Article

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia

2021-08-24

Abstract excerpt

Activating mutations in the KIT tyrosine receptor kinase confer an adverse prognosis for patients with acute myeloid leukemia (AML). Outside of bone marrow transplantation, treatment options are limited. Here we demonstrate combined KIT and LSD1 inhibition produces synergistic cell death against KIT mutant AML cells. This combination suppresses MYC expression to drive cell cycle exit and apoptosis. This decreased...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3f776ab5-e27d-5a3c-a331-a43fa6ae4201
DOI: 10.1101/2021.08.24.456354

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemiaDOI 10.1101/2021.08.24.456354Read

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.Semantic proximity Read

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsSemantic proximity Read

Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemiaSemantic proximity Read

Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its coreSemantic proximity Read

Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid LeukemiaSemantic proximity Read

Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.Semantic proximity Read

LSD1 inhibition modulates transcription factor networks in myeloid malignanciesSemantic proximity Read

Combinatorial inhibition of LSD1 and Menin induces therapeutic differentiation in AMLSemantic proximity Read

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemiaSemantic proximity Read

Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AMLSemantic proximity Read

Advances Toward Lsd1 Inhibitors for Cancer TherapySemantic proximity Read

Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3 -ITD Mutant/ TP53 Wild-type Acute Myeloid LeukemiasSemantic proximity Read